Provided by Tiger Trade Technology Pte. Ltd.

Cumberland Pharmaceuticals

7.65
+0.15002.00%
Post-market: 7.650.00000.00%19:30 EDT
Volume:34.80K
Turnover:260.82K
Market Cap:114.42M
PE:-10.34
High:7.65
Open:7.52
Low:7.34
Close:7.50
52wk High:8.45
52wk Low:1.85
Shares:14.96M
Float Shares:8.75M
Volume Ratio:0.38
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7398
EPS(LYR):-0.1909
ROE:-14.39%
ROA:-2.91%
PB:6.56
PE(LYR):-40.07

Loading ...

Cumberland Pharmaceuticals Q2 Loss Widens After Apotex Transaction

Reuters
·
Aug 05

Cumberland Pharmaceuticals Q2 Adjusted EPS USD -0.2

THOMSON REUTERS
·
Aug 05

Cumberland Pharmaceuticals Q2 FY26 Net Loss Widens to USD 4.1 Million; Revenue Falls 56.28% to USD 166,458

Reuters
·
Aug 05

Cumberland Q2 Adj. EPS $(0.20) Down From $(0.13) YoY, Sales $166.458K Down From $380.797K YoY

Benzinga Earnings
·
Aug 05

Cumberland Pharmaceuticals Reports Company Update & Q2 2026 Financial Results

THOMSON REUTERS
·
Aug 05

Cumberland Declares Special Dividend, Approves $5 Million Share Buyback

MT Newswires Live
·
Jul 13

Cumberland board authorizes $5M share repurchase program

TIPRANKS
·
Jul 13

Cumberland Pharmaceuticals - Authorizes Open-market Share Repurchase Program of up to $5 Mln

THOMSON REUTERS
·
Jul 13

Cumberland Pharmaceuticals Announces Special Dividend of $1.50 Per Share

THOMSON REUTERS
·
Jul 13

Press Release: Cumberland Pharmaceuticals Announces Special Dividend of $1.50 PER SHARE

Dow Jones
·
Jul 13

Cumberland Pharmaceuticals Closes USD 100 Million Branded-drug Sale to Apotex Unit

Reuters
·
Jul 01

Press Release: Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals

Dow Jones
·
Jul 01

Cumberland Pharma Updates Phase 2 FIGHT DMD Trial Data Showing 5.4% LVEF Gain with Ifetroban in Duchenne Cardiomyopathy

Reuters
·
Jun 26

Cumberland Pharmaceuticals Shareholders Approve Apotex-linked Asset Sale Proposal at Special Meeting

Reuters
·
Jun 26

RedHill Biopharma posts corporate presentation on Talicia commercialization and GI-focused pipeline

Reuters
·
Jun 15

Cumberland announces data from Phase 2a clinical trial of ifetroban

TIPRANKS
·
Jun 02

Cumberland Pharmaceuticals, Vanderbilt Health Report Positive Phase 2a Results for Ifetroban in Metastasis Prevention Study

MT Newswires Live
·
Jun 02

Cumberland Pharmaceuticals - No Serious Adverse Events Related to Ifetroban or Placebo Identified

THOMSON REUTERS
·
Jun 02

Cumberland Pharmaceuticals - Phase 2a Trial Meets Primary Endpoint for Safety and Tolerability of Ifetroban

THOMSON REUTERS
·
Jun 02

Cumberland Pharmaceuticals -Co and Vanderbilt Announce Phase 2a Trial Data for Ifetroban in High-Risk Solid Tumors

THOMSON REUTERS
·
Jun 02